ULK1 and neoplasm: To discover potential drug candidates for the NSCLC therapy, the pharmacophore modeling and SAR based on the ULK1 structure (PDB ID: 4WNO) were conducted by Sun et al. [22], resulting in the compound 3S having good inhibitory activity against tumor cells, and the ULK1 kinase was discovered (Figure 2b).